logo
  

Roche's Entrectinib Shrinks Tumors Harboring NTRK, ROS1 Or ALK Gene Fusions

Swiss drug major Roche (RHHBY) said that its investigational medicine Entrectinib shrank tumours in all 11 children and adolescents who had neurotrophic tyrosine receptor kinase, ROS1 or anaplastic lymphoma kinase fusion-positive solid tumours in a phase I/II study, dubbed STARTRK-NG. Complete responses were observed in 2 patients with tumours harbouring NTRK and ALK fusions.

In the study, of the 11 patients, five patients with primary high-grade tumours in the central nervous system or CNS had an objective response, including one patient with a complete response.

"We are encouraged by the results we have seen with Entrectinib in children with paediatric and adolescent cancers, including those with tumours in the brain," said Sandra Horning, Roche's Chief Medical Officer and Head of Global Product Development.

The safety profile of Entrectinib was consistent with that seen in previous analyses, the company said.

Entrectinib for both the treatment of paediatric and adult patients with NTRK fusion-positive, locally advanced or metastatic solid tumours who have either progressed following prior therapies or as an initial therapy when there are no acceptable standard therapies, and for the treatment of people with metastatic ROS1-positive NSCLC is under priority review by the FDA.

The FDA expects to make a decision on approval by August 18, 2019.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
When Can We Expect Starlink to Go Public? This question got an answer from Tesla and SpaceX CEO Elon Musk, who said he will only publicly list SpaceX's satellite internet service Starlink when its revenue is more predictable. Musk was responding to a users tweet, "Any thoughts on Starlink IPO we would love to invest in the future. Any thoughts on first dibs for Tesla retail investors?" John David McAfee, who founded the antivirus software company McAfee Associates, has been found dead in a prison cell in Spain shortly after a Spanish court agreed to extradite him to the US to face tax evasion charges, multiple reports said. He was arrested in Spain in October 2020 after being accused of failing to file tax returns for four years. While reporting financial results for the first quarter of fiscal 2022 on Thursday, drugstore chain Rite Aid Corp. (RAD) initiated its adjusted loss and total revenue guidance for the full-year 2022, below analysts' estimates. For fiscal 2022, the company now projects an adjusted loss in a range...
Follow RTT